MENU
+Compare
JAGX
Stock ticker: NASDAQ
AS OF
Jul 10, 04:59 PM (EDT)
Price
$2.58
Change
-$0.05 (-1.90%)
Capitalization
3.48M

JAGX Jaguar Health Inc Forecast, Technical & Fundamental Analysis

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea... Show more

JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for JAGX with price predictions
Jul 09, 2025

JAGX's RSI Indicator ascends from oversold territory

The RSI Indicator for JAGX moved out of oversold territory on July 08, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 59 similar instances when the indicator left oversold territory. In of the 59 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for JAGX just turned positive on June 10, 2025. Looking at past instances where JAGX's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JAGX advanced for three days, in of 177 cases, the price rose further within the following month. The odds of a continued upward trend are .

JAGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JAGX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for JAGX entered a downward trend on July 09, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.955) is normal, around the industry mean (17.327). P/E Ratio (0.009) is within average values for comparable stocks, (59.374). JAGX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.418). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (0.097) is also within normal values, averaging (272.335).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. JAGX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JAGX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of pharmaceuticals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Generic
Address
200 Pine Street
Phone
+1 415 371-8300
Employees
49
Web
http://www.jaguar.health
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PRFX1.400.02
+1.45%
PainReform Ltd
CCBG41.660.42
+1.02%
Capital City Bank Group
EMCG12.15N/A
N/A
Embrace Change Acquisition Corp
VCEL41.23-0.27
-0.65%
Vericel Corp
FFIV299.89-2.39
-0.79%
F5, Inc.

JAGX and Stocks

Correlation & Price change

A.I.dvisor tells us that JAGX and RNAZ have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that JAGX and RNAZ's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAGX
1D Price
Change %
JAGX100%
N/A
RNAZ - JAGX
31%
Poorly correlated
-1.37%
DVHGF - JAGX
27%
Poorly correlated
N/A
TAOX - JAGX
26%
Poorly correlated
+12.08%
SLNO - JAGX
26%
Poorly correlated
-9.23%
ACET - JAGX
26%
Poorly correlated
+3.76%
More